Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

OMTH Proposed IPO Non-Starter

|Includes: Amarin Corporation PLC (AMRN)

Omthera proposes IPO. Good luck with that, having similar efficacy as Lovaza but several years behind. Not as effective as Vascepa as treatment, and I would say not a candidate for FDA approval with any sort of protection (read: Generic Lovaza will make Epanova meaningless). With their current therapy, not a candidate for expanding indication.